Oculus receives FDA clearance for novel, spray-based wound care formulation

Oculus Innovative Sciences announced that it has received FDA 510(k) clearance for its Alevicyn SG Antipruritic Spray Gel to treat dermatologic conditions like burning and itching skin, as well as skin irritation, lacerations, abrasions and minor burns.

The product was indicated for use as both a prescription and an over-the-counter medication.

The therapy, deemed a medical device by the FDA, enters a market dominated by topical corticosteroids, so its unique form of administration sets it apart from the competitors.

The therapy also has an advanced wound care formulation that uses the patented Microcyn technology, the company says. Oculus says the technology provides superior product stability due to the deployment of hypochlorous acid, which preserves the microorganisms within the gel.

The manufacturing process of Microcyn-based products involves the electrochemical treatment of dilute saltwater, according to the company website.

Citing GlobalData, Oculus says the market for therapies to treat atopic dermatitis will reach $810 million by 2016, with about 70% of the demand from the U.S. And the Alevicyn launch release says topical steroids often lose their effectiveness after a few weeks.

Earlier, the company launched an animal health unit and 6 new Microcyn products for the treatment of wounds, skin and eyes.

- read the release